Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer

Prior treatment

• Self-reported regular use (using 10 or more days in the 30 days prior to randomization) of a THC containing cannabinoid product
• Patients initiating or receiving immunotherapy, a chemotherapy-immunotherapy combination, or non-standard cytotoxic chemotherapy (including patients enrolled/ enrolling in trials of investigational cancer-directed treatments)

Other illness

• Patients with a history of intolerance or hypersensitivity to cannabis (i.e., cannabis hyperemesis)
• Patients with Alzheimer's dementia, active epilepsy, or history of traumatic brain injury
• Has any condition that in the opinion of the investigator might jeopardize the safety of the subject or interfere with protocol compliance

Lab values

• Uncontrolled acute or chronic medical conditions, psychiatric conditions or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for enrollment in this study

Other

• Patients with known active or untreated brain metastases. A brain MRI is not required during the screening period.
• Women who are pregnant, breastfeeding or of childbearing potential without the use of birth control

• Adults (aged 18 or more at enrollment)
• Histologically or cytologically proven pancreatic or colorectal cancer. Histologies may include listing of adenocarcinoma, poorly differentiated carcinoma, or other pathology terms that treating oncologist would consider managing per usual standard of care of pancreas and colorectal adenocarcinoma. Neuroendocrine tumors are excluded in both cancer types.
• Advanced stage (locally advanced or metastatic) pancreatic or colorectal cancer with no definitive plans for curative surgery in the next 3 months
• Self-report of experiencing nausea, vomiting, anorexia, cachexia (wasting), or pain at least once in the 14 days prior to randomization
• Plan to initiate or initiated within the past 2 weeks standard-of-care systemic chemotherapy (any regimen that does not include immunotherapy) at a participating institution with no prior systemic therapy in the prior 3 months (prior adjuvant or neoadjuvant chemotherapy is allowed as long as it was \>3 months prior to randomization)
• Must be a resident of Minnesota
• Must be willing to be registered in the Minnesota Medical Cannabis Program and follow all rules and requirements of the state program
• Must be willing to report baseline and required patient-reported outcomes